Background Fatigue is one of the most disabling symptoms in primary Sjogren’s syndrome (pSS) and it significantly impacts patient’s quality of life[1]. However, the cause of this symptom remains ...

1 University Hospitals of Strasbourg, French National Reference Center for Rare Auto-immune Diseases (RESO), Department of Rheumatology, Strasbourg, France 2 Maple Health Group, LLC, New York, United ...

Background: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). Peresolimab demonstrated superiority to placebo in Disease ...

1 Alice Ho Miu Ling Nethersole Hospital, Department of Medicine, Tai Po, Hong Kong (SAR) 2 The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, ...

Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...

Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...

1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...

1 University Hospital Tuebingen, Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and ...

Objectives Although T cells have been implicated in the pathogenesis of systemic sclerosis (SSc), a comprehensive study of T-cell-mediated immune responses in the affected skin of patients with ...

Correspondence to Professor Ling Qin, Prince of Wales Hospital, Hong Kong, China; lingqin{at}cuhk.edu.hk; Professor Kingston King-lun Mak, Joint Center for Musculoskeletal Research, Guangzhou ...

Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...